Cisplatin induces acute kidney injury by downregulating miR ‐30e‐5p that targets Galnt3 to activate the AMPK signaling pathway

Abstract Cisplatin nephrotoxicity is an etiological factor for acute kidney injury (AKI). MicroRNA (miRNA) expression is dysregulated in cisplatin‐induced AKI (cAKI) although the underlying mechanisms are unclear. A cAKI model was established by intraperitoneally injecting cisplatin, and key miRNAs were screened using high‐throughput miRNA sequencing. The functions of key miRNAs were determined using the cell viability, live/dead, reactive oxygen species (ROS), and 5‐ethynyl‐2′‐deoxyuridine (EdU) proliferation assays. Additionally, the macrophage membrane was wrapped around a metal–organic framework (MOF) loaded with miRNA agomir to develop a novel composite material, macrophage/MOF/miRNA agomir nanoparticles (MMA NPs). High‐throughput miRNA sequencing revealed that miR‐30e‐5p is a key miRNA that is downregulated in cAKI. The results of in vitro experiments demonstrated that miR‐30e‐5p overexpression partially suppressed the cisplatin‐induced or lipopolysaccharide (LPS)‐induced downregulation of cell viability, proliferation, upregulation of ROS production, and cell death. Meanwhile, the results of in vivo and in vitro experiments demonstrated that MMA NPs alleviated cAKI by exerting anti‐inflammatory effects. Mechanistically, cisplatin downregulates the expression of miR‐30e‐5p, and the downregulated miR‐30e‐5p can target Galnt3 to activate the adenosine 5‘‐monophosphate activated protein kinase (AMPK) signaling pathway, which promotes the progression of AKI. Our study found that miR‐30e‐5p is a key downregulated miRNA in cAKI. The downregulated miR‐30e‐5p promotes AKI progression by targeting Galnt3 to activate the AMPK signaling pathway. The newly developed MMA NPs were found to have protective effects on cAKI, suggesting a potential novel strategy for preventing cAKI.